The University of Chicago Header Logo

Connection

Ravi Salgia to Safety

Back to Details
This is a "connection" page, showing publications Ravi Salgia has written about Safety.
Ravi Salgia
Connection Strength
0.019
Safety
  1. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2008 Jul; 110(1):49-55.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.